HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acting Commissioner Von Eschenbach Made Permanent In Time For New Year

This article was originally published in The Rose Sheet

Executive Summary

Andrew von Eschenbach can delete "acting" from his office nameplate; the Senate confirmed him as FDA commissioner Dec. 7 by a comfortable 80-11 margin, ending months of "holds" on the vote and opposition to his nomination from both sides of the aisle
Advertisement

Related Content

FDA Head Von Eschenbach Resigning In January; Industry Awaits Successor
FDA Head Von Eschenbach Resigning In January; Industry Awaits Successor
New staff chief for von E
New staff chief for von E
FDA Clearance Process May Thwart 2010 Monograph Goal – ONP’s Ganley
Nanotechnology Benefits/Risks Presented To FDA Nanotech Task Force
Nanotechnology Benefits/Risks Presented To FDA Nanotech Task Force
Advertisement
UsernamePublicRestriction

Register

RS014396

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel